Background: Esophageal varices is one of the major complications of portal hypertension and one of the main causes of death in cirrhotic patients, so prophylaxis from esophageal varices bleeding can decrease the number of deaths in those patients. Aim of the work: To assess the effect of non-selective beta blockers on portal vein diameter and grades of esophageal varices. Subjects and methods: Our study was carried out at Gastroenterology and Hepatology unit, Internal Medicine department, Zagazig University hospital. Forty patients with HCV positive liver cirrhosis were enclosed in the study. All were Child Pugh grade A and B, diagnosed by clinical examination, laboratory investigations (hepatitis C virus antibody, hepatitis C virus RNA by polymerase chain reaction, hepatitis B virus surface antigen, liver and kidney functions, complete blood count, INR and alpha feto-protein) and pelvi-abdominal ultrasound findings. Upper gastrointestinal (GI) endoscopy was done at the beginning of the study for detection and grading of esophageal varices (EVs) and those without EVs were excluded, also portal vein diameter (PVD) was recorded by ultrasound. The maximum tolerated dose of Propranolol (decrease pulse rate by 25% but not below 60 beats per minute) was given to all patients for three months. EVs grading, by upper GI endoscopy, and PVD were reassessed at the end of the study. Results: Propranolol showed a significant reduction in heart rate and PVD for the pre and posttreatment results after three months of treatment (P<0.001 for both). The dose of Propranolol didn't show significant effect on reduction of small size EVs (P=0.07) while the percent of reduction of PVD correlated significantly with percent of reduction in EVs grade for the pre and post-treatment (P<0.05). A cut off point for detection of significant EVs (GII and III) was 12.5 mm with sensitivity 82.4%, specificity 47.8%, positive predictive value (PPV) 53.8% and negative predictive value (NPV) 78.6%. Conclusion: Non-selective beta blocker (Propranolol) caused significant reduction in portal vein diameter and the percentage of reduction of portal vein diameter significantly correlated with change in esophageal varices grades.
INTRODUCTION
ortal hypertension is caused by increase in resistance, blood flow or both of the portal circulation and worsens if portal collateral blood flow increases. In case of cirrhosis the resistance often occurs within the liver, but it can be also pre or post-hepatic. Portal hypertension is usually asymptomatic till complications develop [1] . Liver cirrhosis and schistosomiasis are the most common causes of portal hypertension. Eighty to ninety percent of asymptomatic cirrhotic patients have elevated hepatic venous pressure gradient (HVPG), 40% of them have esophageal varices (EV). From the rest, 6% per year will develop varices [2] .
Most of The definite way to diagnose portal hypertension is measuring HVPG or upper gastrointestinal (GI) endoscopy to assess the presence of esophageal varices (EVs) and both are considered minimally invasive procedure [6] .
It is difficult to treat portal hypertension unless treatment of underlying cause. Portal venous pressure can be reduced by non-selective beta blockers (NSBBs) and also by creating an anastomosis between portal and hepatic veins by using shunt procerures (eg, Trans-jagular intrahepatic porto-systemic shunt) [7] .
As EVs bleeding has a high morbidity and mortality, primary prevention of bleeding is the main concern in the management of portal hypertension. Non-selective betablockers such as propranolol and nadolol block the adrenergic dilatation of mesenteric arterioles and reduce portal venous inflow [8] .
Both NSBBs and esophageal varices ligation (EVL) can be used in prevention of first variceal hemorrhage in patients with medium to large-sized varices and the choice should be based on local resources, patient characteristics and expertise. Methods After getting a written informed consent from all patients they were asked to undergo; full history taking and full physical examination, then pelvi-abdominal ultrasound and laboratory investigations (complete blood count, liver and kidney functions, INR, HCV antibodies, detection of HCV DNA by polymerase chain reaction, HBsAg and Alpha-feto protein) were done.
The maximum tolerated dose of NSBBs (Propranolol), decrease pulse rate by 25%, but not <60 beats per minute [11], were given to all patients for three months, then all the work up that was done at the beginning of the study were repeated.
STATISTICAL ANALYSIS
All data were statistically assembled in mean ± standard deviation (SD) (in normally distributed data), range and median (in skewed data distribution), or percentages and frequencies if available. Numerical variables were compared between the studied Groups using Mann Whitney (U) test for independent samples when comparing 2 Groups. When comparing more than 2 Groups, Kruskal Wallis test was used. To represent the accuracy of tests, sensitivity and specificity were used. We used receiver operator characteristic (ROC) analysis to detect the best cut off value for the studied variables. To define the significant independent predictors for the presence, grade of EVs and occurrence of significant EVs, univariate and multivariate regression models were made. P values <0.05 was considered statistically significant. The computer program SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 18.0 for Microsoft Windows was used for all statistical calculations. RESULTS The mean±SD of portal vein diameter (PVD) at the pre-treatment results was 12.8±1.34 mm, while the post treatment was 11.4±1.93 mm (P<0.001). As regard the gender, the mean±SD of PVD in females was 12.66±1.49 mm while in males it was 12.8±1.27 mm (P=0.09). There was positive significant correlation between PVD and the age of the patients (P<0.05), but there wasn't any significant correlation between BMI and PVD.
At the pre-treatment endoscopic evaluation of the studied group there was 23 patients (57.5%) had grade I (GI) EVs, 16 patients (40%) had GII and only one patient (2.5%) had GIII EVs, while at the post treatment evaluation 5 patients (12.5%) had no EVs, 24 patients (60%) had GI, 7 patients (17.5%) had GII and 4 patients (10%) hag GIII EVs (P=0.07).
The mean daily dose of NSBBs (Propranolol) used was 66.95±17 mg which caused a significant reduction in the mean of pulse rate from; 79.05±9.02, pre-treatment, to 61.15±4.73, post-treatment (P value <0.001).
The maximum percentage of reduction in PVD was 14.35% and was seen with Propranolol dose 60 mg/day There was significant difference in the mean±SD of PVD for small (GI) EVs 12.1±1.08 mm and significant (GII and III) EVs 13.5±1.28 mm at the pre-treatment evaluation (P<0.001), while the posttreatment evaluation showed 10.2±2.48 mm for G0 EVs, 11±1.74 mm for GI and 12.6±1.43 mm for GII and III (P<0.01). There was a positive significant correlation between percent of change of PVD and EVs grade (r=0.33 and P<0.05).
There was significant correlation between Propranolol dose and PVD at the pretreatment results (P=0.02), while correlation was very highly significant between EVs grade and PVD at the pre and post-treatment results (P<0.001 and 0.007 respectively). 
DISCUSSION
The maximum tolerated dose of Propranolol used at the study, that achieved a 25% reduction in pulse rate but not below 60 bests per minute, ranged from 30 to 80 mg per day (mean± SD of 66.96±17) this dose differ from the dose of the study done by Pimenta et al they used a dose 1 -3.1 mg\kg\day, however the median age in their study was 7.9 years old and the patients were having different etiologies for cirrhosis which may have an effect on the dose used [12] .
There was a very high significant reduction in the pre-treatment heart rate which ranged from 60 to 95 (mean±SD of 79.05±9.02), while the post-treatment showed a range of 54 to 71 (mean±SD 61.15±4.73) (P<0.001). Our maximum percentage of reduction (-14.35%) was less than that of the study done by Groszmann et al, which was 17%, but they used Timolo instead of Propranolol and also the sample size was larger (213 patients) [13] .
There was a very high significant decrease in portal vein diameter (P<0.001) between the pre and post-treatment (mean± SD was 12.8±1.34 and 11.4±1.93 mm respectively). This result was nearly the same as the study done by Groszmann et al, in the effect of beta blockers on the portal vein pressure as they obtain a P value of 0.07 but they used the hepatic venous pressure gradient instead of portal vein diameter and used Timolol instead of Propranolol [13] .
As a noninvasive predictor for significant EVs, portal vein diameter was a weak test as we found, according to our results, at the pretreatment results that 12.5 mm can be used as a cutoff point for prediction of significant EVs with sensitivity 82%, specificity 47.8%. The post treatment results showed a cutoff value 11.5 mm with sensitivity 72.7%, specificity 62.5%. In another study done by Schepis and his colleagues, they found that 13 mm PVD is a cut off point for presence of EVs [14] .
As regard the effect of NSBBs of the EVs size we got nearly the same results as Calés et al. in our study there was a nonsignificant difference in the EVs grade regarding the pre and post-treatment results and there was also a non-significant correlation between the dose of NSBBs and the percent of reduction of EVs size, while Calés et al found that 31% of patients on Propranolol developed large EVs while the percentage was only 17% in the placebo group [15] . Those results was different from that of Feu et al, as they found a reduction in HVPG by 20% in after propranolol therapy, but apart from the HVPG they used for assessment of portal hypertension, their study was done over 28 months and that may be the cause of difference [16] . Our results was also not the same as Merkel et al, as they found that the cumulative risk for developing large varices was 20% in beta blockers group versus 51% in placebo group (P < 0.001), but they used Nadolol and those results was after 5 years treatment and follow up 
